Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements research found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://joycei651voi4.slypage.com/profile